Articles tagged with: dementia
ABILIFY MAINTENA® (a-BIL-i-fy main-TEN-a) (aripiprazole)
ABILIFY MAINTENA® (a-BIL-i-fy main-TEN-a) (aripiprazole)
for extended-release injectable suspension, for intramuscular use
MEDICATION GUIDE
What is the most important information I should know about ABILIFY MAINTENA?
Each injection of ABILIFY MAINTENA must be administered by a healthcare professional only.
ABILIFY …
SINEMET® CR 50 mg/200 mg Controlled-Release Tablets
SINEMET® CR 50 mg/200 mg Controlled-Release Tablets
NAME OF THE MEDICINAL PRODUCT
SINEMET® CR 50 mg/200 mg Controlled-Release Tablets
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet of ‘Sinemet CR’ contains carbidopa (equivalent to 50 mg of anhydrous carbidopa) …
ARISTADA® (air-is-TAH-dah) (aripiprazole lauroxil)
ARISTADA® (air-is-TAH-dah) (aripiprazole lauroxil)
extended-release injectable suspension, for intramuscular use
MEDICATION GUIDE
What is the most important information I should know about ARISTADA?
Each injection of ARISTADA must be administered by a healthcare professional only.
ARISTADA may cause serious side …
REXULTI® (REX-ul-TE) (brexpiprazole) Tablets
REXULTI® (REX-ul-TE) (brexpiprazole) Tablets
MEDICATION GUIDE
What is the most important information I should know about REXULTI?
REXULTI may cause serious side effects, including:
Increased risk of death in elderly people with dementia-related psychosis. Medicines like REXULTI can raise …
Latuda-lurasidone
Latuda-lurasidone
Package leaflet: Information for the patient
Latuda® 18.5 mg film-coated tablets; Latuda® 37 mg film-coated tablets; Latuda® 74 mg film-coated tablets
This medicine is subject to additional monitoring. This will allow quick identification of new safety …
Invega-Paliperidone
Invega-Paliperidone
Package leaflet: Information for the user
INVEGA 1.5 mg prolonged-release tablets; INVEGA 3 mg prolonged-release tablets; INVEGA 6 mg prolonged-release tablets; INVEGA 9 mg prolonged-release tablets; INVEGA 12 mg prolonged-release tablets
Read all of this leaflet carefully …
